

Carlo Chiesa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484318/publications.pdf>

Version: 2024-02-01

97
papers

4,596
citations

109137

35
h-index

102304

66
g-index

102
all docs

102
docs citations

102
times ranked

3483
citing authors

#	ARTICLE	IF	CITATIONS
1	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
2	MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ¹⁷⁷ Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 151-162.	2.8	235
3	EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1238-1250.	3.3	217
4	EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1405-1412.	3.3	204
5	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1393-1406.	3.3	199
6	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1976-1988.	3.3	179
7	Association between [¹⁸ F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1429-1434.	3.3	161
8	EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 192-200.	3.3	156
9	Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective. <i>Frontiers in Oncology</i> , 2014, 4, 210.	1.3	139
10	Radioembolization of hepatocarcinoma with ⁹⁰ Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	3.3	128
11	Sentinel node in breast cancer procedural guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2154-2159.	3.3	114
12	Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1380-1389.	3.3	109
13	EANM procedure guideline for treatment of refractory metastatic bone pain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1934-1940.	3.3	109
14	Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 3190-3210.	0.7	108
15	Clinical and dosimetric considerations for ⁹⁰ Y: recommendations from an international multidisciplinary working group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1695-1704.	3.3	104
16	Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (⁹⁰ Y) microspheres: the experience of the National Tumor Institute of Milan. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 168-97.	0.4	101
17	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
18	Correlation of dose with toxicity and tumour response to ⁹⁰ Y- and ¹⁷⁷ Lu-PRRT provides the basis for optimization through individualized treatment planning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2426-2441.	3.3	94

#	ARTICLE	IF	CITATIONS
19	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 223-230.	3.3	88
20	The Low Hepatic Toxicity per Gray of ⁹⁰ Y Glass Microspheres Is Linked to Their Transport in the Arterial Tree Favoring a Nonuniform Trapping as Observed in Posttherapy PET Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 135-140.	2.8	75
21	EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1682-1699.	3.3	72
22	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. <i>EJNMMI Physics</i> , 2017, 4, 27.	1.3	71
23	High-Dose Yttrium-90 ⁹⁰ Y Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.	0.8	68
24	Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1915-1936.	3.3	66
25	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. <i>EJNMMI Physics</i> , 2017, 4, 28.	1.3	65
26	EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. <i>EJNMMI Physics</i> , 2021, 8, 77.	1.3	61
27	The Influence of Blood Glucose Levels on [18F]Fluorodeoxyglucose (Fdg) Uptake in Cancer: A Pet Study in Liver Metastases from Colorectal Carcinomas. <i>Tumori</i> , 1997, 83, 748-752.	0.6	58
28	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1783-1786.	3.3	48
29	Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3018-3032.	3.3	44
30	EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours. <i>EJNMMI Physics</i> , 2020, 7, 15.	1.3	44
31	Preequilibrium (p,n) reaction as a probe for the effective nucleon-nucleon interaction in multistep direct processes. <i>Physical Review C</i> , 1990, 41, 2010-2020.	1.1	43
32	Emission of ²³ F and ²⁴ Ne in cluster radioactivity of ²³¹ Pa. <i>Physical Review C</i> , 1992, 46, 1939-1945.	1.1	42
33	A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 503-8.	0.4	42
34	Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1699-1700.	3.3	39
35	Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 54, 84-91.	0.4	38
36	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 152-154.	3.3	34

#	ARTICLE	IF	CITATIONS
37	(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 100-13.	0.4	34
38	Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 546-61.	0.4	33
39	Nuclear structure effects in the exotic decay of 225Ac via 14C emission. Nuclear Physics A, 1993, 562, 32-40.	0.6	31
40	Dosimetry in nuclear medicine therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 2-4.	0.4	31
41	Discovery of oxygen radioactivity of atomic nuclei. Nuclear Physics A, 1993, 556, 115-122.	0.6	29
42	Carbon radioactivity of 221Fr and 221Ra and the hindered decay of exotic odd-A emitters. Nuclear Physics A, 1994, 576, 21-28.	0.6	29
43	Neon radioactivity of uranium isotopes. Physical Review C, 1991, 44, 888-890.	1.1	27
44	Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. Medical Physics, 2019, 46, 5403-5406.	1.6	26
45	The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 634-638.	3.3	25
46	Dosimetry in nuclear medicine therapy: radiobiology application and results. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 205-21.	0.4	25
47	Energy response of LR-115 cellulose nitrate to alpha-particle beams. International Journal of Radiation Applications and Instrumentation Part D, Nuclear Tracks and Radiation Measurements, 1991, 18, 321-324.	0.6	23
48	The Italian multicentre dosimetric study for lesion dosimetry in 223 Ra therapy of bone metastases: Calibration protocol of gamma cameras and patient eligibility criteria. Physica Medica, 2016, 32, 1731-1737.	0.4	22
49	First observation of spontaneous fission and search for cluster decay of Th232. Physical Review C, 1995, 51, 2530-2533.	1.1	21
50	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 322-328.	0.9	21
51	Dosimetry in Myeloablative 90Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 113-120.	0.7	20
52	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1745-1757.	3.3	19
53	Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 122-129.	3.3	18
54	Impact of SPECT corrections on 3D dosimetry for liver transarterial radioembolization using the patient relative calibration methodology. Medical Physics, 2016, 43, 4053-4064.	1.6	18

#	ARTICLE	IF	CITATIONS
55	166Ho microsphere scout dose for more accurate radioembolization treatment planning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 744-747.	3.3	18
56	The Contribution of Positron Emission Tomography (Pet) with 18F-Fluorodeoxyglucose (Fdg) in the Preoperative Detection of Axillary Metastases of Breast Cancer: The Experience of the National Cancer Institute of Milan. <i>Tumori</i> , 1997, 83, 542-543.	0.6	17
57	Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1215-1216.	2.8	16
58	The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 915-917.	3.3	16
59	Current Status and Future Direction of Hepatic Radioembolisation. <i>Clinical Oncology</i> , 2021, 33, 106-116.	0.6	16
60	Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 326.	3.5	15
61	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰ Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976.	0.8	14
62	Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). <i>Physica Medica</i> , 2021, 89, 317-326.	0.4	14
63	Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 515-21.	0.4	13
64	Calibration of BP-1 phosphate glass with heavy-ion beams. <i>International Journal of Radiation Applications and Instrumentation Part D, Nuclear Tracks and Radiation Measurements</i> , 1991, 18, 325-327.	0.6	11
65	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods. <i>Cancers</i> , 2022, 14, 959.	1.7	11
66	Impact of missing attenuation and scatter corrections on ^{99m} Tc-MAA SPECT 3D dosimetry for liver radioembolization using the patient relative calibration methodology: A retrospective investigation on clinical images. <i>Medical Physics</i> , 2018, 45, 1684-1698.	1.6	10
67	A System for the automatic monitoring and safe disposal of short-lived radioactive gaseous compounds from hot-cells in a PET facility. <i>Applied Radiation and Isotopes</i> , 1996, 47, 717-722.	0.7	8
68	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. <i>Journal of Nuclear Medicine</i> , 2017, 58, 862-862.	2.8	8
69	High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. <i>Blood</i> , 2006, 108, 3047-3047.	0.6	8
70	A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 53, 658-70.	0.4	7
71	Dosimetry in 131I-mIBG therapy: moving toward personalized medicine. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 57, 161-70.	0.4	7
72	Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer. <i>International Journal of Oncology</i> , 1996, 8, 693-9.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 548-549.	3.3	6
74	The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres. Physica Medica, 2016, 32, 169-170.	0.4	4
75	[18F]FDG synthesis by Anatech RB-86 robotic system: Improvements and general considerations. Journal of Radioanalytical and Nuclear Chemistry, 1998, 230, 45-51.	0.7	3
76	Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. Clinical and Translational Imaging, 2013, 1, 423-432.	1.1	3
77	Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 2047-2048.	0.2	3
78	The impact of time-of-flight, resolution recovery, and noise modelling in reconstruction algorithms in non-solid-state detectors PET/CT scanners: " multi-centric comparison of activity recovery in a 68Ge phantom. Physica Medica, 2020, 75, 85-91.	0.4	3
79	Update on radioligand therapy with ¹⁷⁷ Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori, 2022, 108, 315-325.	0.6	3
80	Radon Indoor Measurements: Results from Sites in the Italian Prealps. Radiation Protection Dosimetry, 1992, 45, 473-476.	0.4	3
81	Spatial density and tumor dosimetry are important in radiation segmentectomy with ⁹⁰ Y glass microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3607-3609.	3.3	3
82	Measurement of exotic decay half lives with track detectors. International Journal of Radiation Applications and Instrumentation Part D, Nuclear Tracks and Radiation Measurements, 1991, 19, 579-584.	0.6	1
83	Radon Indoor Measurements: Results from Sites in the Italian Prealps. Radiation Protection Dosimetry, 1992, 45, 473-476.	0.4	1
84	HCC Radioembolization with Yttrium-90 Glass Microspheres (TheraSphere). , 2018, , 119-125.		1
85	1105P Predictive factors of adverse events onset in GEPNET patients treated with PRRT. Annals of Oncology, 2021, 32, S913.	0.6	1
86	Radiobiology and Radiation Dosimetry in Nuclear Medicine. , 2017, , 305-349.		1
87	Spontaneous emission of ¹⁴ C clusters from A=221 nuclei. Zeitschrift für Physik A, 1994, 349, 309-310.	0.9	0
88	Simultaneous transmission-emission attenuation correction in mediastinal staging of lung cancer. Lung Cancer, 2000, 29, 259.	0.9	0
89	Radioiodine Therapy of Differentiated Thyroid Cancer. , 2013, , 133-153.		0
90	Radionuclide Therapy of Neuroendocrine Tumors. , 2013, , 57-83.		0

#	ARTICLE	IF	CITATIONS
91	P999 Y90-RADIOEMBOLIZATION FOR INTERMEDIATE/ADVANCED HCC PATIENTS OUTSIDE THE CONVENTIONAL CRITERIA MAY BE DETRIMENTAL: A SINGLE CENTER EXPERIENCE. Journal of Hepatology, 2014, 60, S407-S408.	1.8	0
92	85. Treatment of hepatocarcinoma with 90Y glass microspheres: Safety and indication of prolonged overall survival thanks to two compartment dosimetric treatment planning. Physica Medica, 2018, 56, 114-115.	0.4	0
93	Dosimetry for 131I mIBG Therapy. , 2018, , 273-280.		0
94	1183P Sequential PRRT and SIRT: Evaluation of safety, toxicity and best sequence treatment in liver dominant GEPNETs. Annals of Oncology, 2020, 31, S781.	0.6	0
95	Spontaneous emission of 14C clusters from A=221 nuclei. , 1995, , 187-188.		0
96	Radiobiology and Radiation Dosimetry in Nuclear Medicine. , 2016, , 1-45.		0
97	Radiation Protection and Dose Optimisation. , 2016, , .		0